Suchen
Q32 Bio Inc
QTTBZur Watchlist hinzufügen
15.140USD
-0.010-0.07%
Handelsschluss 07-27 16:00（ET）Kurse um 15 Minuten verzögert
186.29MMarktkapitalisierung
5.43KGV TTM
mehr Informationen über Q32 Bio Inc Unternehmen
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Q32 Bio Inc Informationen
BörsenkürzelQTTB
Name des UnternehmensQ32 Bio Inc
IPO-datumMar 28, 2018
CEOMorrison (Jodie Pope)
Anzahl der mitarbeiter42
WertpapierartOrdinary Share
GeschäftsjahresendeMar 28
Addresse830 Winter Street
StadtWALTHAM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02451
Telefon17819990232
Websitehttps://www.q32bio.com/
BörsenkürzelQTTB
IPO-datumMar 28, 2018
CEOMorrison (Jodie Pope)
Führungskräfte von Q32 Bio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Q32 Bio Inc?
Die fünf größten Anteilseigner von Q32 Bio Inc sind: Dr. Shelia M. Violette, Ph.D.
Wie viele Institutionen halten Anteile an Q32 Bio Inc (QTTB)?
Mit Stand vom 2026Q1 halten 189 Institutionen Anteile an Q32 Bio Inc, mit einem Gesamtmarktwert von etwa 9.99M, was 65.09% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2048479.00 gestiegen.